Sign in
Taking people in United StatesNo phase

Comparing fluid plans for sudden kidney injury in people with cirrhosis

Compares a fluid guide and albumin for kidney injury in cirrhosis.

Key facts

Who runs it
Massachusetts General Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
Status
Recruiting
People taking part
50 people, planned
Started
12 Sept 2024
Expected to end
1 May 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Recommendation: No Further Resuscitation
  • Recommendation: Resuscitation with Crystalloid
  • Recommendation: Resuscitation with Colloid
  • Recommendation: Standard of Care IV Albumin
Record updated
13 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in hospital with decompensated cirrhosis and a sudden drop in kidney function (acute kidney injury). It compares two ways of giving IV fluids.

Age
18 years or older
Sex
All sexes
Disease stage
Decompensated cirrhosis, known before or found on admission, with acute kidney injury by International Club of Ascites (ICA) criteria. People must be admitted to hospital.
Earlier treatment
People who already received more than 200 g albumin during this hospital stay cannot join. People with a past liver or kidney transplant cannot join.
Biomarker or test result
SCr (blood creatinine) rise of ≥0.3 mg/dL (27 µmol/L) within 48 hours, or ≥50% rise from baseline within the prior 7 days.

Main reasons for not taking part

  • In the intensive care unit, on a breathing machine, or needing more than 2 liters of extra oxygen
  • Shock needing vasopressors (terlipressin, midodrine and octreotide for the kidneys are allowed)
  • Hepatic encephalopathy (brain problems from liver disease) grade 3 or 4, or NYHA class 3-4 heart failure
  • Severe active bleeding needing 3 or more units of red blood cells in the past 48 hours
  • Pregnant or breastfeeding, or allergy to IV albumin

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Adult age 18 years or greater
  • Signed informed consent form (ICF) by any subject capable of giving consent, or, when the subject is not capable of giving consent, by their legally authorized representatives prior to initiation of any study procedures
  • Admitted to the hospital
  • Diagnosis of decompensated cirrhosis (either prior to admission or new diagnosis on admission)
  • Presence of acute kidney injury (AKI) as defined by International Club of Ascites (ICA) criteria, defined as SCr increase of ≥0.3 mg/dL within 48 hours or ≥50% increase from baseline which is known or presumed to have occurred within the prior 7 days

Who cannot take part

  • Death, liver transplant, or renal replacement therapy (RRT) expected within 48 hours
  • Severe, active bleeding requiring 3 or more units of red blood cell transfusion in the 48 hours prior to screening
  • History of prior liver or kidney transplant
  • Presence of New York Heart Association (NYHA) class 3-4 symptoms of congestive heart failure at the time of screening
  • Any condition, in the opinion of the investigator, that could confound or interfere with the safe completion of study activities
  • Allergy or other contraindication to IV albumin administration
  • Already received >200 g albumin during admission at the time of screening
  • Requiring >2 liters (L) supplemental oxygen at the time of screening
  • In shock requiring vasopressors (vasoconstrictors for the treatment of AKI such as terlipressin, midodrine, and octreotide are allowed)
  • Patient and/or legally authorized representative unable to provide informed consent
  • Hepatic encephalopathy grade 3 or 4 at the time of screening
  • Admission to the intensive care unit at the time of screening
  • Mechanical ventilation at the time of screening
  • Pregnant or nursing status

Where in United States

  • Massachusetts General HospitalBoston, United StatesContact: Sydney Whittaker, BSTaking people

About the trial

What the trial wants to find out

The goal of this interventional study is to evaluate two strategies for how to provide intravenous (IV) fluids for treating patients with acute kidney injury (AKI) in cirrhosis. The main question it aims to answer is: what is the safety, efficacy, and feasibility of providing a recommendation to use a Volume Assessment Guidance Algorithm (VAGA) or give standard of care doses of IV albumin?

Read full original descriptionShow less

Patients will be randomly assigned where their treating teams will receive a VAGA-based recommendation or a standard of care IV albumin recommendation.

The 2 groups in the trial

  • VAGA GroupTreatment being tested

    This group will receive an algorithm-based recommendation based on the 2024 Acute Disease Quality Initiative (ADQI)/International Club of Ascites (ICA) joint consensus meeting on AKI in cirrhosis, which recommends a personalized approach to AKI in cirrhosis in order to avoid volume overload. This includes balanced crystalloids as first-line resuscitative fluids unless there is a patient-specific indication for an alternative colloid (e.g. blood for gastrointestinal bleeding, IV albumin for spontaneous bacterial peritonitis or suspicion of hepatorenal syndrome), or no further resuscitation.

    Treatment: Recommendation: No Further Resuscitation, Recommendation: Resuscitation with Crystalloid, and Recommendation: Resuscitation with Colloid

  • Standard of CarePlacebo, for comparison

    This group will receive a recommendation based on the 2021 American Association for the Study of Liver Diseases (AASLD) and 2018 European Association for the Study of the Liver (EASL) clinical practice guidelines, which recommends a 1 g/kg/d IV albumin (maximum 100 g/day) IV albumin over 2 days as an initial resuscitation approach for patients with AKI and cirrhosis.

    Treatment: Recommendation: Standard of Care IV Albumin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Initial Resuscitation for Acute Kidney Injury in Patients With Cirrhosis: A Pilot Randomized Trial Using a Volume Assessment Guidance Algorithm
Plain-language title
Comparing fluid plans for sudden kidney injury in people with cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 March 2026